Background: A spin-off from Shire plc (NASDAQ:SHPG), Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) is a niche pharmaceutical company. To date, it has not just one but two areas of specialization: it operates in the neurology space with a neuro-psych pipeline, and at least so far, it only develops controlled-release products.
It released Q2 results Tuesday, which showed rapid growth of its two marketed products. It also provided additional positive news and a positive outlook. Trading well below its highs in both time and price, and now trading at an extraordinarily low price:sales ratio, SUPN now appears to be on the bargain counter. As disclosed in my article published Monday, I have written about SUPN before on Seeking...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|